Bharat Parenterals
Healthcare
BPLPHARMA NSE
₹1,800.60 No trade today
- P/E
- Not meaningful: loss-making over the last twelve months
Close 4 Nov 2026 ₹1,800.60 +600.60 +50.1% 1Y
Start ₹1,200.00
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- −1.87%
- Debt to Equity
- 0.45
- EPS (TTM)
- −₹22.35
- Book Value
- ₹481.93
- Market Cap
- —
- P/E (TTM)
- Not meaningful: loss-making over the last twelve months
- P/B
- 3.74
- ROE
- −2.54%
- Dividend Yield
- 0.05%
- EBITDA
- ₹25.40 Cr
- 52W High
- ₹2,295.10
- 52W Low
- ₹880.25
- Volume
- 0
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Bharat Parenterals (this company) | ₹1,800.60 | — | ₹1,293 Cr | 3.74 | 0.05% | −2.54% | −1.87% | ₹323 Cr | −₹30 Cr |
| Median 8 companies | ₹1,787.00 | 38.81 | ₹1,25,337 Cr | 4.57 | 0.44% | 16.25% | 16.65% | ₹22,862 Cr | ₹3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
42 Weak
Data confidence 93/100
Category scores
- Quality
- 46
- Average
- Returns, margins, earnings quality 22% weight
- Valuation
- 35
- Poor
- Cheap vs sector & own history 24% weight
- Growth
- 3
- Poor
- Sales & profit trajectory 9% weight
- Financial Health
- 29
- Poor
- Solvency, leverage, coverage 9% weight
- Momentum
- 79
- Strong
- Trend strength, vol-adjusted 12% weight
- Ownership
- 44
- Weak
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
No strengths listed
Weaknesses
8- Stock is trading at 4.02 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -0.79% over last 3 years.
- Company might be capitalizing the interest cost
- Earnings include an other income of Rs.9.60 Cr.
- Company has high debtors of 159 days.
- Promoter holding has decreased over last 3 years: -6.64%
- Working capital days have increased from 100 days to 143 days
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Bullish | 6 | 6 | 7 |
| Oscillators | Bearish | 2 | 6 | 1 |
| Moving Averages | Strong Bullish | 4 | 0 | 6 |
Oscillators
Bearish
Bearish
2
Neutral
6
Bullish
1
Overall
Bullish
Bearish
6
Neutral
6
Bullish
7
Moving Averages
Strong Bullish
Bearish
4
Neutral
0
Bullish
6
Key readings
- RSI (14)
- 49.34
- Neutral
- MACD (12,26,9)
- 49.63
- Bearish
- SMA (50)
- 1,704.68
- Bullish
- SMA (200)
- 1,346.84
- Bullish
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | +10.77% |
|---|---|
| 5Y | +10.97% |
| 3Y | +16.53% |
| 1Y | +1.47% |
| TTM | −11.19% |
Net profit
| 10Y | Turned to loss |
|---|---|
| 5Y | Turned to loss |
| 3Y | Turned to loss |
| 1Y | Loss narrowed by ₹17 Cr |
| TTM | Loss narrowed by ₹5.71 Cr |
Operating cash flow
| 10Y | Zero base |
|---|---|
| 5Y | +9.63% |
| 3Y | +19.98% |
| 1Y | Turned positive |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | −3.42 pp |
|---|---|
| 5Y | −7.56 pp |
| 3Y | −4.53 pp |
| 1Y | +3.46 pp |
| TTM | −0.03 pp |
Revenue by year
| Mar 2017 | ₹111 Cr |
|---|---|
| Mar 2018 | ₹137 Cr |
| Mar 2019 | ₹220 Cr |
| Mar 2020 | ₹228 Cr |
| Mar 2021 | ₹205 Cr |
| Mar 2022 | ₹212 Cr |
| Mar 2023 | ₹218 Cr |
| Mar 2024 | ₹261 Cr |
| Mar 2025 | ₹340 Cr |
| Mar 2026 | ₹345 Cr |
Net profit by year
| Mar 2017 | ₹7.00 Cr |
|---|---|
| Mar 2018 | ₹9.00 Cr |
| Mar 2019 | ₹21.00 Cr |
| Mar 2020 | ₹24.00 Cr |
| Mar 2021 | ₹20.00 Cr |
| Mar 2022 | ₹21.00 Cr |
| Mar 2023 | ₹16.00 Cr |
| Mar 2024 | ₹11.00 Cr |
| Mar 2025 | −₹44.00 Cr |
| Mar 2026 | −₹27.00 Cr |
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 69.91 | 59.81 | 59.82 | 67.82 | 92.51 | 71.63 | 72.26 | 104 | 116 | 64.62 | 65.19 | 99.62 | 93.74 |
| Expenses | 59.46 | 55.49 | 53.21 | 66.82 | 88.02 | 79.29 | 68.62 | 102 | 102 | 63.79 | 63.45 | 100 | 85.21 |
| Operating Profit | 10.45 | 4.32 | 6.61 | 1 | 4.49 | −7.66 | 3.64 | 2.23 | 13.78 | 0.83 | 1.74 | −0.52 | 8.53 |
| OPM % | 14.95% | 7.22% | 11.05% | 1.47% | 4.85% | −10.69% | 5.04% | 2.14% | 11.88% | 1.28% | 2.67% | −0.52% | 9.1% |
| Other Income | 2.1 | 2.6 | 1.26 | 2.64 | 2.54 | 4.21 | 2.94 | 1.93 | 1.06 | 3.53 | 1.33 | 3.63 | 1.11 |
| Interest | 0.89 | 0.63 | 0.58 | 1.13 | 2.77 | 2.91 | 3.33 | 3.94 | 3.69 | 3.11 | 2.9 | 2.85 | 2.45 |
| Depreciation | 1.58 | 1.75 | 1.82 | 3.87 | 9.03 | 9.01 | 8.76 | 8.52 | 8.6 | 8.56 | 8.46 | 8.63 | 8.69 |
| PBT | 10.08 | 4.54 | 5.47 | −1.36 | −4.77 | −15.37 | −5.51 | −8.3 | 2.55 | −7.31 | −8.29 | −8.37 | −1.5 |
| Tax % | 30.46% | 46.48% | 33.46% | 88.24% | 85.32% | 13.92% | 43.01% | 13.61% | 133.73% | 17.65% | 16.77% | −2.51% | 138% |
| Net Profit | 7.01 | 2.43 | 3.64 | −2.56 | −8.84 | −17.51 | −7.88 | −9.44 | −0.87 | −8.6 | −9.67 | −8.16 | −3.56 |
| EPS (₹) | 13.02 | 6.05 | 6.5 | −0.52 | 1.96 | −11.5 | −2.42 | −6.86 | 11.94 | −10.49 | −6.37 | −6.96 | 1.47 |
Profit & Loss
₹ Cr| Particulars | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 124 | 111 | 137 | 220 | 228 | 205 | 212 | 218 | 261 | 340 | 345 | 323 |
| Expenses | 114 | 105 | 124 | 191 | 200 | 179 | 183 | 198 | 234 | 337 | 330 | 313 |
| Operating Profit | 10 | 7 | 12 | 29 | 28 | 25 | 29 | 20 | 27 | 4 | 16 | 11 |
| OPM % | 8% | 6% | 9% | 13% | 12% | 12% | 14% | 9% | 10% | 1.1% | 4.6% | 3.3% |
| Other Income | 5 | 8 | 7 | 13 | 11 | 9 | 7 | 12 | 5 | 11 | 10 | 10 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 13 | 13 | 11 |
| Depreciation | 4 | 6 | 6 | 6 | 6 | 6 | 7 | 6 | 9 | 35 | 34 | 34 |
| PBT | 9 | 7 | 13 | 35 | 33 | 27 | 28 | 24 | 19 | −34 | −21 | −25 |
| Tax % | 31% | 8% | 29% | 39% | 26% | 25% | 25% | 33% | 44% | 29% | 27% | — |
| Net Profit | 6 | 7 | 9 | 21 | 24 | 20 | 21 | 16 | 11 | −44 | −27 | −30 |
| EPS (₹) | 11.26 | 12.03 | 15.92 | 37.09 | 42.13 | 35.59 | 36.45 | 28.47 | 24.95 | −18.33 | −11.88 | −22.35 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 3% | 4% | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. | — |
Balance Sheet
₹ Cr| Particulars | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 7 |
| Reserves | 51 | 58 | 67 | 88 | 112 | 138 | 160 | 177 | 191 | 324 | 315 |
| Borrowings | 19 | 6 | 9 | 5 | 1 | 12 | 18 | 50 | 158 | 180 | 146 |
| Other Liabilities | 44 | 40 | 50 | 60 | 68 | 43 | 42 | 118 | 149 | 138 | 145 |
| Total Liabilities | 120 | 110 | 132 | 159 | 188 | 199 | 226 | 350 | 504 | 649 | 613 |
| Fixed Assets | 35 | 31 | 34 | 35 | 33 | 45 | 41 | 42 | 211 | 252 | 255 |
| CWIP | 0 | 0 | 0 | 1 | 12 | 0 | 26 | 99 | 25 | 31 | 35 |
| Investments | 0 | 1 | 1 | 1 | 0 | 43 | 11 | 0 | 0 | 5 | 6 |
| Other Assets | 85 | 79 | 98 | 121 | 142 | 111 | 148 | 209 | 268 | 360 | 317 |
| Total Assets | 120 | 110 | 132 | 159 | 188 | 199 | 226 | 350 | 504 | 649 | 613 |
Cash Flow
₹ Cr| Particulars | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 0 | −2 | 6 | 20 | 14 | 24 | −1 | 22 | −5 | −27 | 38 |
| Investing | 0 | −2 | −8 | −9 | −13 | −43 | −7 | −78 | −105 | −137 | 9 |
| Financing | 0 | −8 | 4 | −4 | −3 | 10 | 9 | 61 | 110 | 156 | −47 |
| Net Cash Flow | 0 | −11 | 2 | 7 | −1 | −8 | 2 | 4 | 1 | −8 | 1 |
| Free Cash Flow | 0 | −4 | −2 | 12 | 0 | 24 | −40 | −68 | −108 | −56 | −1 |
| CFO/OP | 0 | −8 | 73 | 107 | 87 | 123 | 16 | 150 | 18 | −444 | 305 |
Ratios
| Particulars | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 130 | 143 | 157 | 106 | 127 | 121 | 126 | 188 | 198 | 184 | 159 |
| Inventory Days | 62 | 70 | 60 | 59 | 71 | 61 | 56 | 100 | 142 | 132 | 162 |
| Days Payable | 171 | 168 | 110 | 83 | 104 | 71 | 64 | 136 | 137 | 136 | 122 |
| Cash Conversion Cycle | 21 | 45 | 107 | 82 | 93 | 111 | 118 | 152 | 202 | 180 | 199 |
| Working Capital Days | 8 | 64 | 78 | 73 | 89 | 106 | 148 | 91 | 81 | 76 | 143 |
| ROCE % | — | 11% | 18% | 39% | 31% | 20% | 17% | 11% | 7% | −4% | −2% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Bharat Parenterals insights
66 extracted metrics across FY01–FY27.
Documents
- Q1 FY27 concall · Aug 2026PPT
- Q4 FY26 concall · May 2026Transcript PPT Recording
- Concall · Jan 2026PPT
- Q2 FY26 concall · Nov 2025Transcript PPT
- Q1 FY26 concall · Jul 2025PPT
Frequently Asked Questions about Bharat Parenterals
What does Bharat Parenterals Ltd do?
Incorporated in 1992, Bharat Parenterals Ltd is in the business of manufacturing and marketing of formulations
Where is Bharat Parenterals Ltd (BPLPHARMA) listed?
Bharat Parenterals Ltd trades as BPLPHARMA on the NSE and under code 541096 on the BSE.
Which sector does Bharat Parenterals Ltd belong to?
Bharat Parenterals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the 52-week high and low of Bharat Parenterals Ltd?
Over the last 52 weeks Bharat Parenterals Ltd has traded between ₹880.25 and ₹2,295.1 as of 4 Nov 2026.
Does Bharat Parenterals Ltd pay dividends?
Bharat Parenterals Ltd has a dividend yield of 0.05%.
What is the Return on Equity (ROE) of Bharat Parenterals Ltd?
Bharat Parenterals Ltd reported a return on equity of -2.54%. Its debt-to-equity ratio is 0.45.
Company Information
Incorporated in 1992, Bharat Parenterals Ltd is in the business of manufacturing and marketing of formulations
Website bplindia.in
CEO Mr. Bharatkumar Rameshchandra Desai
Employees 393
Listed 21 Mar 2018
Face Value ₹10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/541096.md for Bharat Parenterals Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.